RecoRNA

RecoRNA is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics and vaccines. Based in Suzhou, China, the company leverages a proprietary platform to engineer circRNA molecules that exhibit superior stability and longer-lasting protein expression compared to conventional linear mRNA. RecoRNA's research focus spans infectious diseases, oncology, and rare genetic conditions, with a pipeline that includes a next-generation COVID-19 vaccine and cancer immunotherapies. The company aims to address the limitations of current RNA technologies by optimizing translation efficiency and reducing immunogenicity. Supported by prominent venture capital firms, RecoRNA is positioned as a leader in the emerging field of circular RNA medicine.